Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Xilio Therapeutics, Inc.
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results
May 08, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting
April 23, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
March 11, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
February 24, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
February 12, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
January 21, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2025
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
December 19, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
December 16, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
November 07, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results
November 07, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
October 30, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
October 04, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
August 08, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors
June 13, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results
May 14, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
April 01, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
March 28, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
February 28, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
January 31, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies
January 08, 2024
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data
December 07, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results
November 09, 2023
From
Xilio Therapeutics, Inc.
Via
GlobeNewswire
Tickers
XLO
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.